Within CRP < 1 mg/L, responders (vs. current MDD) show mainly inhibition of immune-related pathways, including interferon (type I) and T cell-related signalling, still with activation of NF-κB signalling, immune cell communication, metabolic pathways, and translational and transcriptional regulators (Table S7 and Fig. S3B). This evidence concerns the gene CRP and major depressive disorder.